Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
With March Madness in full swing, we decided to stick with what we know here at The Motley Fool, trading our basketball picks in for stock picks. We formed our own bracket filled with the top Big Pharma and Big Biotech stocks in a winner take-all tournament as determined by the collective intelligence of our CAPS community.
This Final Four matchup is a heavyweight bout between Celgene and Johnson & Johnson. Watch and find out what J&J and embattled Rutgers University have in common and whether Celgene's style of play is enough to advance to the championship round.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today, simply click here now.